Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2025-11-16
Based on 496 first isolates · MED-A · Cystitis (lower UTI) · 2024-11-17 → 2025-11-16
Internal medicine A
Per-organism detail: MED-A urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
nitrofurantoin 82 % (79 %–85 %)
No tissue or blood levels: cystitis only.
Not covered: Proteus mirabilis (7 %), Klebsiella pneumoniae (5 %), Pseudomonas aeruginosa (5 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
meropenem MEM
trend · Escherichia coli reserve
84 %
92 %
n = 26
nitrofurantoin NIT
trend · Escherichia coli lower UTI only
82 %
88 %
n = 26
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
80 %
85 %
n = 26
mecillinam MEC
trend · Escherichia coli lower UTI only
78 %
88 %
n = 26
ceftriaxone CRO
trend · Escherichia coli
78 %
92 %
n = 26
ciprofloxacin CIP
trend · Escherichia coli
78 %
88 %
n = 26
72 %
88 %
n = 26
trimethoprim TMP
trend · Escherichia coli lower UTI only
67 %
65 %
n = 26
48 %
54 %
n = 26
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
13 %
8 %
n = 26
5 %
0 %
n = 26
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
3 %
0 %
n = 26

Most likely organisms for this profile

Escherichia coli
56 %
Klebsiella pneumoniae
11 %
Enterococcus faecalis
10 %
Proteus mirabilis
7 %
Pseudomonas aeruginosa
5 %
Citrobacter freundii
3 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.